Yicheng Guo

The paper develops a monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants and identifies differences in antibody-evasion profiles between JN.1 and BA.3.2 lineages.

This study evaluates antibody evasion and ACE2 receptor engagement of SARS-CoV-2 variant RW.1.1, finding reduced receptor binding but no increased serum resistance compared to other variants.

This study finds that young children have lower neutralizing antibody titers against BA.3.2.2 compared to adults, despite similar titers against dominant variants, suggesting age-related differences in susceptibility.

This study generates 19 human monoclonal antibodies to track antigenic evolution of H5N1 clade 2.3.4.4b, identifying epitope-specific neutralization patterns and antigenic differences between viral genotypes.

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

This study evaluates VYD2311, a new monoclonal antibody, showing it neutralizes multiple SARS-CoV-2 variants more effectively than pemivibart, making it a potential candidate for immunocompromised individuals.

This study isolates and characterizes V2 apex-directed neutralizing antibodies from SHIV-infected macaques, revealing structural and genetic features that enable broad neutralization.

This study optimizes a human monoclonal antibody to enhance its neutralization of SARS-CoV-2 variants, including subvariants XEC and LP.8.1, through structural analysis and engineering.

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

This study evaluates pemivibart's neutralizing activity against recent SARS-CoV-2 JN.1 sublineages and finds it has substantially reduced potency against KP.3.1.1.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

This study performs a meta-analysis of exhausted CD8+ T cells in humans and mice to identify robust therapeutic targets for immunotherapy.

This study identifies two new PAH risk genes, FBLN2 and PDGFD, through rare variant analysis of 4,241 PAH cases, with de novo variants contributing to ~15% of pediatric IPAH.

cAb-Rep is a curated database of human B cell immunoglobulin sequence repertoires, providing annotated datasets for studying antibody diversity and prevalence.

The paper develops a web server to predict anti-HIV activity of compounds and identifies 7 approved drugs repurposed as anti-HIV agents.